Cancer Diagnostics Market Analysis

Cancer Diagnostics Market Analysis

To get key market trends

  Download Free Sample

Based on application, the market is divided into tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. The imaging segment is further bifurcated into ultrasound and radiology, mammography, MRI scan, PET scan, CT scan, SPECT, and other imaging. The imaging segment dominated the market accounting for 63.6% of revenue share in 2024.
 

• The segment is estimated to witness significant growth owing to the increasing adoption towards breast cancer screenings along with the rising number of awareness programs, leading to numerous women undergoing diagnosis for breast cancer.
   
• Introduction of technologically advanced products such as computer-aided images to detect cancer in dense breast tissue which will further boost the market size.
   

Based on cancer type, the cancer diagnostics market is bifurcated into bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney cancer, leukemia, liver and lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, thyroid cancer, and other cancer types. The liver and lung cancer segment accounted for a 18.4% market share in 2024 and is projected for significant growth to reach USD 65.5 billion by 2034.
 

• Unhealthy dietary habits, increased smoking and alcohol consumption as well as other environmental factors are the major impact rendering factors in the market growth. Tobacco consumption is the key factor that has escalated the number of lung cancer cases across the globe.
   
• According to World Health Organization (WHO), consumption of tobacco is responsible for the death of approximately 7 million people each year, globally. Moreover, nearly 80% of the smokers live in low and middle-income countries.
   
• Furthermore, increasing prevalence of lung and liver cancer in emerging economies will further foster segmental growth. The liver-lung cancer segment will foresee significant growth over the projected period owing to the increasing prevalence of cancer across globe especially liver and lung cancer.
   
• Thus, the growing prevalence of liver-lung cancer among the population base will propel the demand for cancer diagnostics.
   

Based on end use, the cancer diagnostics market is bifurcated into hospitals, diagnostic laboratories, diagnostic imaging centers, and cancer research institutes.
 

• Hospitals segment held a significant revenue share in 2024 and is predicted to witness similar growth during the forecast period.
   
• High adoption rates for technologically advanced biopsy, mammography, and other devices utilized in treatment of cancer will increase the number of diagnoses carried out in hospital settings.
   
• Furthermore, availability of skilled professionals to operate advanced cancer diagnosis equipment as well as favorable reimbursement policies for various cancer diagnosis procedures performed in hospital settings will surge the segment revenue.
   

• The U.S. cancer diagnostics market is projected to grow significantly, reaching USD 135 billion by 2034.
   
• The incidence of cancer in the U.S. is on the rise due to several factors, including an aging population, lifestyle choices such as smoking and sedentary behavior, and environmental exposures.
   
• According to projections from the American Cancer Society, around 2,001,140 new cancer cases and 611,720 cancer-related deaths are expected in 2024, stimulating the demand for effective diagnostic tools.
   

The cancer diagnostics market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Innovative diagnostic technologies are transforming cancer care in the UK. The development and adoption of advanced methods, such as liquid biopsy, molecular diagnostics, and next-generation sequencing (NGS), are enhancing the ability to detect cancers earlier and with greater accuracy.
   
• These advancements enable healthcare providers to identify specific cancer types and their genetic mutations, which are essential for personalized treatment strategies.
   

Japan cancer diagnostics market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The trend toward personalized medicine is gaining momentum in Japan. As healthcare providers increasingly adopt treatment strategies tailored to individual patient profiles based on genetic and molecular information, the need for precise and reliable diagnostic tests will continue to rise. This focus on personalized approaches will be crucial in enhancing treatment outcomes for cancer patients.
   

The cancer diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Awareness of the importance of early cancer detection and screening is increasing among the Saudi population. Public health campaigns and initiatives, such as the Ministry of Health’s National Campaign for Breast Cancer Awareness, are actively educating people about cancer risks and the advantages of regular screenings.
   
• Therefore, as participation in these programs grows, the demand for cancer diagnostic services is anticipated to rise.